1SXP Stock Overview
Develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 1SXP from our risk checks.
SCHOTT Pharma AG & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €27.00 |
| 52 Week High | €43.20 |
| 52 Week Low | €25.48 |
| Beta | 0 |
| 11 Month Change | -14.88% |
| 3 Month Change | -15.52% |
| 1 Year Change | -5.92% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -13.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1SXP | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0.2% | 2.2% | 0.2% |
| 1Y | -5.9% | 3.6% | 8.5% |
Return vs Industry: 1SXP underperformed the German Life Sciences industry which returned 3.6% over the past year.
Return vs Market: 1SXP underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 1SXP volatility | |
|---|---|
| 1SXP Average Weekly Movement | 6.1% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 1SXP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 1SXP's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1884 | 4,681 | n/a | www.schott-pharma.com |
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. The company offers prefillable glass or polymer syringes, glass vials, cartridges, and ampoules. Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; and SCHOTT TOPPAC unique, a polymer container.
SCHOTT Pharma AG & Co. KGaA Fundamentals Summary
| 1SXP fundamental statistics | |
|---|---|
| Market cap | €4.10b |
| Earnings (TTM) | €150.41m |
| Revenue (TTM) | €948.56m |
27.3x
P/E Ratio4.3x
P/S RatioIs 1SXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1SXP income statement (TTM) | |
|---|---|
| Revenue | €948.56m |
| Cost of Revenue | €624.35m |
| Gross Profit | €324.20m |
| Other Expenses | €173.79m |
| Earnings | €150.41m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Dec 12, 2024
| Earnings per share (EPS) | 1.00 |
| Gross Margin | 34.18% |
| Net Profit Margin | 15.86% |
| Debt/Equity Ratio | 24.5% |
How did 1SXP perform over the long term?
See historical performance and comparison